Dybly develops pharmaceutical products for patients affected by the build-up of atherosclerotic plaques.

Dybly has licensed its program DYB186

DYB186
Stimulate body‘s own ability to reduce the cholesterol content of plaques and prevent infarction with a chronic oral treatment